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Abstract: Palliative care in Parkinson’s disease (PD) has developed significantly in the past five years. The 
presence of unmet palliative care need, similar to that in malignant conditions, is well established, but may 
not always be identified by clinicians in everyday practice. To address this, clinicians must be able to rapidly 
identify, triage, assess and address unmet needs and monitor response to intervention. This is also central to 
establishing integrated models of care for PD. Systematic evaluation of need can be facilitated by structured 
assessment tools, and several such tools have now been described for PD. This article reviews the palliative 
care assessment tools which have been developed for PD, both for patients and also for caregivers. It sets 
out the psychometric properties of these tools and describes the way in which they may be applied within an 
overall, systematic assessment of unmet need.
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Introduction
Palliative care for Parkinson’s disease (PD) has developed 
significantly over the past five years. It is established that 
people living with PD, in the latter stages of the disease, 
face similar challenges, with an equivalent palliative care 
need, to those with malignant conditions (1,2). 
In  l i ne  w i th  the  WHO de f in i t i on  (3 )  and  a s 
recommended by the National Institute for Health 
and Care Excellence (NICE) in the UK (4), palliative 
interventions may be appropriate even from the time of 
diagnosis, alongside other active medical interventions, for 
example help with information management (5) and access 
to and support with advance care planning (ACP) (6).
Why measure palliative care needs in PD?
In practice, equitable access to palliative care for People 
with Parkinson’s (PwP) based on need, depends on 
integrated models of care delivery (7). This combines a 
palliative approach to care, delivered by non-palliative 
specialists as part of usual practice and access to specialist 
palliative care (SPC) services on the basis of need (8). This 
model mirrors approaches to palliative provision for other 
non-malignant conditions and is based upon effective 
identification and triage of unmet care needs, by non-
palliative specialists. 
Tools and measures which support assessment and 
documentation of both prevalence of unmet needs 
and response to intervention in routine clinical care 
are available. These help us judge the benefit of needs 
assessment, can drive year on year improvement in clinical 
outcomes and contribute to service development (9).
Within an integrated system of care different methods 
for assessing unmet need will be appropriate at different 
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times. For example, detailed quantitative assessment may 
not be feasible or desirable in everyday PD clinic, where a 
faster screening approach may be preferred. Whereas, in 
SPC clinic a quantifiable measure of need may be extremely 
useful to assess change over time and response to treatment. 
Thus, different palliative assessment tools may be required 
at various points in the patient journey.
What do we mean by needs assessment?
A needs assessment tool has been defined as that which 
provides a consistent and comprehensive system to prompt 
discussion of a patients’ range of support and care needs; 
helps professionals triage tailored action and is useful 
for audit and service planning (10). This is based on the 
recognition that systematic assessment has advantages 
over usual medical consultation or open-ended questions, 
facilitating the identification of greater number of symptoms 
and increased recognition of distressing symptoms (11). 
Such assessment should not focus solely on medical issues, 
but embrace a holistic model of care, considering spiritual, 
psychological and existential needs. 
In other conditions, this integrated approach to palliative 
care has been shown to improve patient outcomes (12,13) 
and studies have identified a number of general palliative 
care assessment tools which allow a systematic review of 
need for patients with cancer (10), or in primary care (12,14). 
Whilst some tools from the latter group have captured PwP 
within their study populations (15,16), they are targeted at 
general primary care populations and in this article we focus 
on those tools which have been developed specifically for 
PwP.
Assessment of palliative care needs in PD may usefully be 
conceptualised in several steps: 
(I) Recognition of those most at greatest risk of unmet 
needs; 
(II) Identification of unmet needs;
(III) Assessment  of  unmet  needs  (may inc lude 
quantification);
(IV) Assessment of change over time and response to 
intervention.
Identifying those at greatest risk of unmet need is 
important in order to focus resource effectively. There is 
no agreed strategy for when best to apply palliative needs 
assessment in PD, but a growing number of studies have 
identified factors associated with poor outcome (17,18). 
Anecdotally, within our own practice, the presence of 
formed visual hallucinations, onset of Hoehn and Yahr 
(H+Y) stage 3 symptoms and recurrent falls are particular 
triggers for early consideration of unmet needs, with the 
aim of engaging in this process before significant cognitive 
impairment is established, to optimise patient autonomy 
and joint decision making.
Type of assessment tool
Respondent
In selecting a needs assessment tool, it is important to 
consider the primary respondent. Patient reported outcome 
measures (PROM) have the obvious advantage of directly 
assessing patient concerns but may be less useful where 
cognitive impairment is prevalent; a particular challenge 
in PD (19,20). Here proxy representation of need may 
be an attractive alternative, although caution is needed 
interpreting proxy reported need (21).
Health related quality of Life (HRQoL)
There are a number of well-established HRQoL tools in 
PD. While HRQoL is an important measure of wellbeing, 
it is distinct from needs assessment which aims to identify 
the most important concerns for the individual and which 
should be priority therapeutic targets (22).
Setting
The most appropriate assessment tool will depend on a 
number of factors, such as the setting of the consultation 
(community or secondary care), focus of the consultation 
– (usual PD care or SPC), patient characteristics (i.e., 
presence of significant cognitive impairment), service 
configuration (integrated or prognostic gateway to palliative 
care), goal of assessment (clinical care or research) and the 
time available. 
This article will focus on: (I) the needs assessments 
tools for PwP, rather than HRQoL assessment, (II) the 
characteristics of each tool and (III) suggest how they may 
fit within the overall assessment of unmet need within an 
integrated PD palliative care service. Although symptom 
specific measures are available, these lie outside the scope of 
this review which focuses on wider needs assessment.
We used a rapid review methodology. A single reviewer 
(ER) screened retrieved titles and abstracts from a limited 
number of electronic databases (Pubmed). The search terms 
“Parkinson(s)”, “Palliat.”, “Assess.” were used PubMed. In 
addition, we drew on grey literature (PhD “Palliative care 
in Parkinson’s disease: development of a needs assessment 
tool” Edward Richfield, University of Hull) to perform a 
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narrative review of the existing palliative care assessment 
tools for use in PwP.
Generalised palliative assessment in PD 
Palliative outcome score-symptoms-PD (POS-S PD)
A common approach to the development of palliative needs 
assessment tools for PD has been to adapt existing tools, 
originally developed for other areas of palliative care. The 
POS (23) is a well-established palliative assessment originally 
validated in malignant conditions and subsequently 
in  non-mal ignant  condit ions  including MS (24) . 
The core POS contains 10 items and forms the basis for 
a number of extended tools, such as the POS-S, where 
question 2 “other symptoms” is extended by adding a list of 
symptoms relating to the condition in question. A version of 
the POS-S has been independently validated for MS (POS-
S-MS) (24) and one was subsequently developed for PD 
(POS-S-PD) (25). Two publications, one cross sectional (25) 
and the other longitudinal (26), report the use of the POS-
S-PD to assess palliative and supportive care need in PwP 
and atypical parkinsonism. Each paper refers to the tool 
with a different name - POS-PD and POS-PP respectively, 
but this appears to represent a single tool, which is now 
available for use on the host website as POS-S-PD. 
There has been no reported independent validation 
of the POS-S-PD, although the core tool on which it is 
based has been well validated in a number of languages and 
the principle of extension to POS-S well described and 
validated in other conditions.
The POS-S-PD uses 20 questions to cover a range 
of motor and non-motor features of PD, each rated by 
the patient as 0 (no effect) to 4 (overwhelming), giving 
maximum total score of 80.
The Core-POS covers 10 palliative care domains 
(pain, other symptoms, patient anxiety, family anxiety, 
information, support, depression, self-worth, wasted time, 
practical matters) again scored 0–4, maximum score 40.
The tools have been used in a cross-sectional study to 
describe symptom burden associated with later stage disease 
(H+Y 3–5) (25). The study population was relatively young 
(mean age 67 at mean disease duration 9.7 years), given the 
average age of diagnosis in PD of 70 years. This is most 
likely to be reflective of a tertiary care centre study setting 
in South East England. People were excluded if care home 
resident, which is important given the high rates of care 
home use in later stage PD (27).
The authors present the scores for Core-POS (10 
questions rated 0–4, total score 40) and POS-S-PD (20 
questions 0–4, total score 80) as separate but complementary 
assessments.
In combination these tools cover a broad range of 
potential palliative needs, focused predominantly on the 
person with PD, with just a single question (family anxiety) 
relating to other members and no explicit assessment of 
caregiver needs. They can be completed on the basis of 
patient or proxy report, which is an important strength.
A key strength of this assessment is the demonstrated 
responsiveness to change over time, with three assessments 
covering a 12–15 month period, in a group with identical 
baseline characteristics (mean age 67, H+Y 3–5) (26). 
IPOS neuro/IPOS NEURO-8
The IPOS NEURO (28) is a development of the POS and 
its related tools, specifically aimed at needs assessment in 
neurological conditions. It asks participants about their need 
in the three days prior to assessment. It starts with a prompt 
for main concerns (free text), followed by 34 symptom 
related questions, a prompt for other symptoms (free text) 
and 8 questions relating to other aspects of need (anxiety in 
patient and family, depression, peacefulness, ability to share 
with friends, information, practical issues, wasted time). 
Eight of the symptom domains (pain, spasms, shortness 
of breath, nausea, vomiting, mouth problems, difficulty in 
sleeping, constipation), were combined in a symptom sub-
scale [IPOS NEURO-8 (28)] and subjected to psychometric 
testing in patients with Multiple Sclerosis, PD, Progressive 
Supra-nuclear Palsy and Multiple System Atrophy. 
Construct validity and test-retest reliability for the 8 
question sub-scale (IPOS NEURO 8) was examined using 
a pooled data set taken from two independent studies, an 
intervention trial in MS and the longitudinal description of 
symptoms in PD and Related Conditions (PDRC) described 
above—data presumably extracted from the POS-S-PD 
scores. The patient characteristics for those with PDRC is 
therefore identical to above (H+Y 3–5, mean age 68, care 
home residents excluded).
Test-Retest at 6 weeks was judged “fair” based on 
Pearson’s correlation coefficient (r=0.58).
Constructs showed moderate levels of validity against 
the PDQ-8 (r=0.48, P<0.05), Non-Motor Symptom 
Questionnaire (r=0.58, P<0.05) and Core POS (r=0.58, P 
value not reported).
It is difficult to judge the external validity of these 
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findings currently. As a standalone tool the IPOS 
NEURO-8 has reasonable psychometric properties, 
although limited by the study population which is not 
representative of PwP at either end of the disease course, 
(excluding H+Y stage 1 and 2, at one extreme and care 
home residents at the other). The, as-yet un-reported, IPOS 
NEURO (only available as supplementary information 
to publication discussed above), containing the IPOS 
NEURO-8 as a subscale, would be useful as it covers a wide 
range of unmet need, including social and psychological 
domains.
IPOS Neuro-s24
The same group have recently published a factor analysis 
of a further assessment tool, the IPOS NEURO-s24 (29), 
which consist of 24 symptom-based questions, including 
those examined above in the IPOS NEURO-8 publications. 
The full version of this is not available currently, so it is 
unclear whether social, spiritual and caregiver domains are 
covered in addition to the 24 symptoms domains. Further 
publications are anticipated.
ESAS-PD
The ESAS-PD (2) is an adaptation of the Edmonton 
Symptom Assessment Scale (ESAS) (30), with the addition 
of 4 PD related domains in addition to the original 10 item 
tool. The modifications were made following a modified 
Delphi process (3 movement disorder specialists), the tool 
asks respondents (patient +/− help from caregiver) to rate 
the following on a 10 point scale: Pain, Tiredness, nausea, 
depression, anxiety, drowsiness, anorexia, wellbeing, 
shortness of breath, other problem, stiffness, constipation, 
dysphagia and confusion. Maximum score is therefore 140.
Domains covered by the ESAS-PD relate to patient, 
rather than caregiver, experience. It is relatively short, 
reducing participant burden when compared with the POS-
S-PD/core POS combination (30 questions).
The ESAS-PD is unique as the only tool in this area with 
published evidence to show responsiveness to intervention. 
Patients in a study mapping unmet need showed a 
significant reduction in ESAS-PD score after a period of 
intervention at a multi-disciplinary clinic.
Similar to the POS, described above, the original ESAS 
has been widely validated in malignant and some non-
malignant conditions (31-33). However, we were unable 
to identify any separate validation studies of the ESAS-
PD. Although there is evidence for change in response to 
intervention, the test-retest and inter-rater reliability to 
ESAS-PD (as opposed to ESAS) are not established. Also, 
whilst measuring presence and severity of symptom, it does 
not provide a patient priority with regard to which are the 
most concerning.
Since its development the ESAS-PD has been used to 
describe palliative care burden in other PD cohorts (34) and 
is included in current study protocols in this area (35).
Palliative care assessment (PACA) tool
PACA tool was developed in cancer as a way to rate the 
severity of patient identified symptoms (36). It was used to 
evaluate the symptom load of PwP in an incident cohort in 
the north of England (1). Participants self-generated a list 
of symptoms and were then prompted regarding additional 
35 common symptoms including motor and non-motor. 
Each symptom then rated as 0 (not present) to 3 (present 
and dominating the day).
As individuals rated a variable number of symptoms, 
depending on how many they self-generated there is no 
summative score. 
The tool was used in PwP but excluded those with 
atypical syndromes. The population was representative, 
including all H+Y stages, with median age 75.4 years. Of 
the 161 patients 38 did not take part and were more likely to 
be older, in nursing homes or with more advanced disease, 
possibly reflecting the relatively high completion burden of 
this tool.
The pooled symptoms generated from the assessments 
were examined using factor analysis. Of the 11 factors 
identified six showed correlation with the Unified 
Parkinson’s Disease Rating Score (UPDRS) (r=0.33–0.58). 
Reliability characteristics were not examined.
The administration time was not recorded, but self-
evidently varied according to the number of symptoms 
generated, the largest recorded being 29 individual 
symptoms.
NAT:Parkinson’s disease
The Needs Assessment Tool Progressive Disease: Cancer 
(NAT:PD-C) was developed in Australia for use in cancer (37) 
and subsequently adapted and validated in non-malignant 
conditions (38-40). It has been adapted for use in PD 
(NAT:PD) (41,42).
It differs from the tools described above in several key 
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areas. It is the only clinician completed tool in this group, it 
does not produce a quantitative summary score, but rather 
each domain is rated for degree of concern (0 no concern 
– 2 significant concern). Where concerns are identified 
users are prompted to triage according to whether the 
unmet need can be addressed by themselves, someone in 
their team, or requires external referral (including, but not 
exclusive to, SPC referral). In addition, it contains at the 
start a prompt to identify PwP at higher risk of unmet needs 
and supplies suggested phrases to use to probe domains for 
those less familiar with this approach.
The NAT:PD contains 13 constructs within 3 domains 
(1—patient wellbeing, 2—ability of carer to care for patient, 
3—carer and family wellbeing). Constructs cover physical, 
psychological, spiritual and existential, financial and inter-
personal aspects of needs, as well as rating information 
needs. As such it may be considered the most holistic if the 
tools discussed in this section, although similar domains 
are covered by the proposed IPOS NEURO. However, 
NAT:PD is a clinician-rated needs assessment tool and not 
an outcome measure, and the IPOS NEURO is patient 
or clinician rated and has the properties of an outcome 
measure, and could be used in conjunction with the 
NAT:PD.
Construct validation of the NAT:PD was conducted in 
a district general hospital population in the UK, with all 
disease stages represented (H+Y 1–5). However, unlike the 
POS-S-PD and IPOS NEURO 8, the validation study did 
not include people with atypical parkinsonian syndromes.
Of the constructs tested (financial needs were not 
tested as no appropriate comparator identified), the level 
of correlation between each construct and the primary 
comparator tool was highly statistically significant for most 
constructs. The authors report good levels of agreement 
(>0.6) for two constructs, moderate (0.4–0.6) for five 
constructs (and fair (0.2–0.4) for four. Lower levels of 
agreement are explained by difficulty matching comparator 
tools to the broad constructs. Validity is further supported 
by the presence of convergent and divergent patterns of 
association.
Inter-rater reliability was assessed using videoed, 
NAT:PD guided, consultations. Reliability was good for 
one construct, moderate for three constructs and fair for 
six constructs. Three constructs failed to demonstrate at 
least fair agreement, although in two of these cases the level 
of percentage agreement was extremely high. This is an 
anomaly of Kappa, which can give poor agreement where 
percentage agreement is very high but not perfect (43), 
and the authors suggest Kappa be interpreted alongside 
percentage agreement in this instance.
The NAT:PD has previously been questioned for the 
time taken for administration (44). This was not assessed 
in the validation studies. However, it is designed for 
use by clinicians as part of routine consultation. Studies 
of the parent tool, in cancer, showed no increase in 
consultation time in an oncology clinic (45). It could also 
be used in conjunction with a patient reported tool such 
as the IPOS NEURO 8, which would highlight the most 
pressing concerns of the patient, thereby streamlining the 
consultation to focus on the most important issues.
Caregivers
Where informal caregivers are present PD can be associated 
with significant caregiver strain (46), which is particularly 
associated with the non-motor components of the disease (47), 
increases with disease severity and may affect younger 
carers to a greater degree than older ones (48). Caregiver 
burden has been the subject of a recent comprehensive 
systematic literature review which included a systematic 
review of available assessment tools (49). Here we 
summarise the characteristics of one instrument validated in 
PD and another identified by the review as being used most 
commonly in studies involving PwP.
Zarit burden interview (ZBI)
ZBI (50) consists of 22 items examining caregiver burden, 
each scored 0 (never) – 4 (almost always), with a total score 
out of 88 and a score of 21 felt to represent a threshold 
for significant burden. The full form has been validated 
in PD (51) with constructs achieving satisfactory levels of 
correlation (r=0.31–0.78). 
These results have been closely replicated in a further 
study of PwP (52), which also examined the criterion 
validity of various short forms of the ZBI (Zarit 12, 8, 7, 6, 
4 and 1), where the ZBI 22 was taken as the criterion gold 
standard. This latter aspect may require some caution in 
interpretation as scores for the short forms were derived 
from the original 22 item questionnaire, rather than 
separate administration. However, the evidence of good 
criterion validity (r=0.87–0.99) open up the opportunity 
to use shortened version of the ZBI in PD, the author 
suggesting that shorter forms may be appropriate for 
screening or where burden is not the central variable under 
examination.
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Parkinson’s disease caregiver burden (PDCB) 
questionnaire
The PDCB has been developed specifically for PD, based 
on interviews with PwP and their caregivers (53). It consists 
of 20 items covering seven domains (Physical burden, sleep 
disruption, patient symptoms, responsibilities, medication 
(patient), social burden, patient and self-relationship).
Face and content validity were checked using patient 
groups and experts in the field. Internal consistency was 
good (Cronbach’s alpha 0.856) although the physical burden 
item was felt to be less reliable and contribute poorly to 
over-all score.
Construct validity, examined against the Caregiver 
Burden Index (CBI), for over-all score was very good 
(r=0.773, P<0.01). This may be anticipated as both tools 
explicitly measure the same variable (caregiver burden), in 
contrast with the tools discussed above. It should be noted 
that the CBI has not been independently validated in PD.
An alternative approach to measuring the impact of care 
on caregivers is to examine caregiver quality of life (QoL). 
Whilst this is not within the remit of the current article, 
it should be noted that tools to examine caregiver QoL 
have been specifically developed for PD (54) and atypical 
parkinsonism (55).
Assessment tools in practice
In practice, the choice of assessment tool (see Table 1) will 
depend on the model of palliative care being delivered and 
the characteristics of the person being assessed. The nature 
of PD means that tools which allow proxy or clinician 
assessment, rather than relying solely on patient reporting, 
will have an important role. Conversely, patient reported 
tools, particularly those such as the PACA, can help to 
prioritise patient concerns within an over-all assessment of 
needs.
In addition, the timing of the consultation, within 
an over-arching model of care, will determine the 
time available and the type of assessment which is 
most appropriate (see Figure 1). Thus, it is likely that a 
combination of tools, at different points in the care model 
and according to individual participant characteristics will 
be necessary.
The challenge of palliative assessment
Several studies suggest a significant burden of unmet 
palliative care needs in PD (1,2,56), which may currently 
be invisible to clinicians. The application of structured 
assessments to PwP is therefore likely to reveal levels of 
palliative need which current services may not be equipped 
to meet. In addition, the need for education, training 
and support for clinicians, and commitment by service 
providers and commissioners must not be under-estimated. 
Implementation work with the Needs assessment Tool 
versions for interstitial lung disease (39) and heart failure (38) 
have both shown that usual care teams need training in 
Table 1 Comparison of general palliative care assessments for PDRD
Name of palliative 
assessment tool
Disease 
stage in 
which tool 
tested
Construct 
validity
Test-retest 
reliability
Inter rater 
reliability
Tested in 
atypical 
Parkinsonian 
syndromes
Respondent 
(patient/caregiver/
both/clinician only)
Established 
clinically 
significant 
change
Burden of completion 
(time/no. questions)
POS-S PD H+Y 3–5 No No No Yes Patient (core-POS 
either patient or 
carer)
– 20 + 10  
(core POS)
ESAS PD Not stated No No No Not stated Patient +/− 
caregiver
Yes 14
IPOS Neuro 8 H+Y 3–5 Yes Yes No Yes Patient No 8
PACA H+Y 1–5 Yes No No No Patient No Variable
NAT:Parkinson’s 
disease
H+Y 1–5 Yes No Yes No Clinician N/A* 13 (no additional 
burden to patient)
*NAT:Parkinson’s disease is not an outcome measure, rather gives a profile of concerns and triaged actions. POS-S PD, palliative outcome 
score-symptoms-PD; ESAS PD, Edmonton Symptom Assessment Score PD; IPOS Neuro 8, Integrated Palliative Outcome Scale neuro 8; 
PACA, palliative care assessment; POS, palliative outcome score; PDRD, Parkinson’s disease and related disorders.
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how to identify, assess and manage symptoms, how to assess 
psychosocial concerns, how to communicate well with 
regard to ACP, how to raise the subject of SPC referral and 
how to develop robust clinical pathways of care including 
SPC (57,58).
The growing evidence identifying predictors of poor 
prognosis in PD and the future possibility of individualised 
prognostication from baseline characteristics (17,18), also 
present a significant challenge and are likely to increase 
the need for supportive interventions earlier in the disease 
course. We need to develop services which acknowledge 
and address these challenges. Through research and service 
evaluation, assessment tools can help us to estimate the 
volume of unmet need, identify priority areas for individual 
and service level development, target clinical and educational 
resource and assess the effectiveness of our interventions. As 
such they are a key component of patient focused care.
Conclusions
A number of palliative care assessment tools have been 
developed or adapted for use in PD. These vary greatly 
in the domains covered, the nature of respondent, burden 
of administration and the degree to which they have been 
formally subjected to psychometric testing. Choice of tool 
will depend upon the setting in which it is to be applied, the 
time available and the stage of disease. The rising rate of 
cognitive impairment in latter stage PD requires particular 
consideration and increases the utility of tools which 
accommodate proxy and clinician responses.
More than one tool may be needed to achieve a 
systematic, holistic assessment of need, perhaps applied at 
different points in the assessment process, with different 
purposes (identification, detailed assessment, quantification 
and response to change). Examining how these tools can 
supplement each other in practice and, most importantly, 
improve patient focused outcomes will be an important area 
of future research.
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to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
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